Education and Training
Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate
This study is the first clinical trial using sodium oxybate for the treatment of REM sleep behavior disorder (RBD). Sodium oxybate is a drug approved by FDA for the treatment of narcolepsy which has been used "off label" to treat patients with severe RBD. This drug has shown to be effective and well tolerated in patients with RBD (Shneerson, 2009; Liebenthal, 2016; Moghadam, 2017).
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Sodium Oxybate
- other: Placebo
Eligibility
Inclusion Criteria:
- 40-85 years old
- With or without Parkinson's disease
- Experiencing RBD episodes on average at least 2x/week or 8x/month
- Able to report RBD episodes themselves or via a partner witness
Exclusion Criteria:
- History of falls during ambulation in the last 6 months despite adequate neurologic
treatment
- Requirement of an ambulatory device at home
- Inadequately treated symptomatic orthostatic hypotension
- BMI > 35
- Untreated or uncontrolled OSA (4%AHI>15)
- Cognitive impairment resulting in inability to comply with treatment instructions
- Pregnancy
Ages Eligible for Study
40 Years - 85 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Emmanuel During
650-721-7561
Not Recruiting